Skip to main content

Table 1 Outcomes of neoadjuvant FOLFIRINOX regimens in locally advanced and borderline resectable pancreatic cancer

From: Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review

Authors Journal, Year Number of Patients Staging System Duration (Cycles) Radiographic Response Surgical Resection R0 Rate Pathological Results
Blazer et al. Ann Surg Oncol 2015 25 LAPC
18 BRPC
AHPBA/
SSO/
SSAT
4.9
(mean)
NA NA NA NA
Boone et al. [14] Surg Oncol, 2013 13 LAPC
12 BRPC
AHPBA/
SSO/
SSAT
5 (mean) PD 1
Intolerable SE 1
5/11 4/5 1 CAP g0
4 CAP g1
Gunturu et al. [54] Med Oncol, 2013 16 LAPC NR 11 (median) PR 8
SD 7
PD 0
2/16 NR 1 near pCR (2 mm residual tumor)
Hosein et al. [55] BMC Cancer, 2012 14 LAPC
4 BRPC
AHPBA/
SSO/
SSAT
6 (median) LAPC (1 PD, 9 RT)
BRPC (1 RT)
LAPC (3/14)
BRPC (3/4)
LAPC (2/3)
BRPC (3/3)
NR
Khushman et al. [56] Pancreatology, 2015 25 LAPC AHPBA/
SSO/
SSAT
8 (median) PD 2 10/25 7/10 NR
Nitsche et al. [18] Ann Surg Oncol, 2015 14 LAPC/
BRPC
NCCN 7 (median) 6 PR, 6 SD, 1 PD 0/14 NR NR
Peddi et al. [57] JOP, 2012 19 LAPC
4 BRPC
NR 4 (median) 1 rCR, 5 PR, 9 SD, 3 PD 4/23 NR NR
Valeri et al. [21] Pancreatology, 2014 1 LAPC MDA 8 NR 1/1 1/1 1 pCR
  1. LAPC locally advanced pancreatic cancer, BRPC borderline resectable pancreatic cancer, AHPBA Americas Hepatopancreatobiliary Association, SSO Society of Surgical Oncology, SSAT Society for Surgery of the Alimentary Tract, NA not available, PD progressive disease, SE side effects, PR partial remission, SD stable disease, rCR radiological complete response, CAP College of American Pathologists grading system, NR not reported, NCCN National Comprehensive Cancer Network, MDA M.D. Anderson